 Galectin Therapeutics Inc. NASDAQ:GALT Director Kevin D. Freeman acquired 5,000 shares of the businesss stock in a transaction dated Friday, September 4th. The stock was purchased at an average price of 2.57 per share, with a total value of 12,850.00. Following the completion of the transaction, the director now directly owns 23,469 shares of the ... 